FDA Approval Activities for this Drug
Zyprexa (olanzapine) Tablets, 2.5, 5, 7.5, 10, 15 & 20 mg, Eli Lilly & Co. NDA 20-592/S18 7/10/03 7/28/03 7/10/03
Zyprexa Indications: Short-term treatment of acute manic episodes associated with Bipolar I Disorder, either as monotherapy (S-006) or in combination with lithium or valproate (S-018).
Zyprexa (olanzapine) Tablets, Eli Lilly & Co. NDA 20-592/SE1-011 11/9/00
Zyprexa Zydis (olanzapine orally disintegrating) Tablets, Eli Lilly & Co. NDA 21-086 Symbyax (Olanzapine & Fluoxetine HCl) Capsules, Eli Lilly & Co., Inc. Zyprexa (olanzapine) Tablets, Eli Lilly & Co. Zyprexa IntraMuscular (olanzapine) Injection, Eli Lilly & Co. | Symbyax (olanzapine and fluoxetine HCl) Capsules, Eli Lilly and Co., Labeling Revision | Olanzapine Tablets, TEVA Pharma, Tentative Approval | Olanzapine Tablets, Mylan Pharma, Tentative Approval | Zyprexa (olanzapine) tablets, Eli Lilly and Co., Labeling Revision | Zyprexa (olanzapine) Tablets, Eli Lilly and Co., Labeling Revision | Zyprexa Zydis (olanzapine) orally disintegrating tablets, Eli Lilly and Co., Labeling Revision | Zyprexa IntraMuscular (olanzapine for injection), Eli Lilly and Co., Labeling Revision | Olanzapine Tablets, Sandoz Inc., Tentative Approval | Zyprexa (olanzapine) tablets, Eli Lilly and Co., Labeling Revision | Zyprexa Zydis (olanzapine) orally disintegrating tablets, Eli Lilly and Co., Labeling Revision | Zyprexa IntraMuscular (olanzapine) injection, Eli Lilly and Co., Labeling Revision | Symbyax (olanzapine and fluoxetine HCl) capsules, Eli Lilly & Co., Labeling Revision | Zyprexa Tablet, Lilly, Labeling Revision | Zyprexa Injection, Lilly, Labeling Revision | Zyprexa Zydis Tablet, Lilly, Labeling Revision | Symbyax (olanzapine/fluoxetine) capsules, Eli Lilly, Labeling Revision | Olanzapine Tablets, Roxane Labs, Tentative Approval | Olanzapine Orally Disintegrating Tablets, Barr Labs, Tentative Approval | Symbyax (olanzapine and fluoxetine HCl) capsules, Eli Lilly, Labeling Revision | Zyprexa (olanzapine) Tablets, Eli Lilly, Labeling Revision | Zyprexa Zydis (olanzapine) orally disintegrating tablets, Eli Lilly, Labeling RevisionZyprexa IntraMuscular (olanzapine) injection, Eli Lilly, Labeling Revision | SYMBYAX (olanzapine and fluoxetine HCl) Capsules, Eli Lilly & Co., Labeling Revision | Zyprexa (olanzapine) Tablets, Eli Lilly & Co., Labeling Revision | Zyprexa Zydis (olanzapine) Orally Disintegrating Tablets, Eli Lilly & Co., Labeling Revision | Zyprexa (olanzapine) Intramuscular Injection, Eli Lilly & Co., Labeling Revision | Olanzapine and Fluoxetine Hydrochloride Capsules, Teva Pharma, Tentative Approval | Symbyax (olanzapine/fluoxetine HCl) capsules, Eli Lilly Co., Labeling Revision | Symbyax (fluoxetine hydrochloride; olanzapine) Capsules, Eli Lilly and Co., Labeling Revision | Symbyax (olanzapine/fluoxetine HCl) Capsules, Eli Lilly & Co., Labeling Revision | Symbyax (fluoxetine hydrochloride and olanzapine) Capsules, Eli Lilly and Co., Labeling Revision | Zyprexa (olanzapine) Intramuscular Injection, Eli Lilly and Co., Labeling Revision | Zyprexa (olanzapine) Tablets, Eli Lilly and Co., Labeling Revision | Zyprexa Zydis (olanzapine) Orally Disintegrating Tablets, Eli Lilly and Co., Labeling Revision | Olanzapine Tablets, Roxane Labs, Tentative Approval